Blood cancer patients in England first in world to be offered ‘Trojan horse' drug
In guidance published on Friday, the National Institute for Health and Care Excellence (Nice) gave the green light to belantamab mafodotin, which can halt the advance of multiple myeloma for three times as long as standard treatments.
The targeted therapy, which is given as an infusion every three weeks with other cancer drugs, is a special type of antibody drug that targets and attaches to cancer cells.
It has been described as a Trojan horse treatment because it works by being taken into a cancer cell and unleashing a high concentration of a lethal molecule to destroy the cell from inside.
Prof Peter Johnson, NHS England's national clinical director for cancer, said the drug would be life-changing for patients and their families.
'Myeloma is an aggressive type of blood cancer, but we have seen a steady improvement in the outlook for patients over recent years as we have introduced new targeted therapies,' he said.
'I am delighted that patients in England will be the first to benefit from this new treatment, which has the potential to keep cancer at bay for years longer, giving people the chance of more precious time with friends and family.'
About 1,500 patients a year in England with multiple myeloma, an incurable cancer of the bone marrow, will benefit from the treatment, also known as Blenrep and made by GlaxoSmithKline.
Health officials said the drug would be offered to patients whose cancer had progressed or failed to respond to another first-line treatment.
Shelagh McKinlay, the director of research and advocacy at the blood cancer charity Myeloma UK, said it was fantastic to see the NHS become the first healthcare system in the world to roll out the drug.
'We have been working very hard for the last year to get this treatment approved and we know it will transform the lives of thousands of people with myeloma,' she said.
Paul Silvester, 60, from Sheffield, described the impact of the drug as amazing after he was diagnosed with myeloma in 2023. After the first treatment he received failed to stop his cancer progressing, he was given belantamab mafodotin through an early access programme at the Royal Hallamshire hospital.
'I feel like this treatment has brought the party balloons back in the house. It has been amazing – within the first two or three weeks, after the first dose, I was in remission,' he said.
Trials suggest the treatment, in combination with bortezomib and dexamethasone, delays progression of the disease by an average of three years, compared with one year for patients taking the commonly used drug daratumumab along with the other treatments.
Helen Knight, the director of medicines evaluation at Nice, said: 'This recommendation demonstrates our commitment to getting the best care to patients fast, while ensuring value for the taxpayer.'
The health minister Karin Smyth said: 'This groundbreaking therapy puts the NHS at the forefront of cancer innovation. By harnessing cutting-edge 'Trojan horse' technology, we're offering new hope to blood cancer patients across the country.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ITV News
10 minutes ago
- ITV News
UK-India trade deal sparks fears over access to cheap medicines for millions
A newly signed trade agreement between India and the UK has triggered concerns that millions of poor Indians may lose access to affordable life-saving medicines. Civil society groups and health experts say the UK-India Free Trade Agreement (FTA), finalised between two countries, tilts the balance in favour of multinational pharmaceutical corporations and threatens to erode long-standing protections that have allowed India to produce low-cost generic drugs. 'This is not just about trade. It's about whether a person living on ₹200 (£2) a day can afford cancer treatment or survive tuberculosis,' said Jyotsna Singh, co-convenor of the Working Group on Access to Medicines and Treatments. At the heart of the controversy are the agreement's intellectual property (IP) provisions, which activists say may restrict the Indian government's ability to issue compulsory licences—legal tools that allow domestic companies to manufacture patented drugs at reduced prices during public health emergencies. India used this provision in 2012 to dramatically cut the price of sorafenib, a cancer drug sold by Bayer under the brand Nexavar. Generic versions slashed the monthly cost by nearly 97%, from ₹2.8 lakh (£2,600) to around ₹8,800 (£80), making it affordable to thousands. 'By discouraging compulsory licensing and promoting voluntary licences, the deal hands over control of access to medicines to the market,' said Prof Biswajit Dhar, a trade expert and former professor at New Delhi's Jawaharlal Nehru University. 'Voluntary licences often come with strings attached and don't bring the same price reductions.' Weakening India's Patent Safeguards Under the FTA, companies will no longer need to report annually how their patents are being 'worked'—or used—in India. Instead, disclosures can be made every three years, and some information can be kept confidential. Activists say this undermines transparency and makes it harder to prove that a drug isn't available to the public, a key step in applying for a compulsory licence. There are also concerns the deal could open the door to 'evergreening'—a tactic in which companies make minor changes to existing drugs and claim new patents. Indian law currently limits this practice under Section 3(d) of the Patents Act, but experts warn the FTA's emphasis on 'harmonisation' of IP standards with Western countries could override such protections. 'This is effectively a backdoor entry for TRIPS-plus provisions,' said K.M. Gopakumar, co-convenor of the Working Group. 'It would push India to grant unnecessary patents, prolonging monopolies and delaying cheaper alternatives.' The Indian pharmaceutical industry supplies more than 60% of global vaccines and a significant share of affordable generics to low- and middle-income countries. Critics say the FTA may limit this capacity and ultimately have consequences well beyond India's borders. Government response The Indian government has promoted the FTA as a landmark deal that will boost exports and attract UK investment in manufacturing, services, and digital trade. Officials insist that India has preserved its ability to protect public health. But rights groups remain unconvinced. 'You cannot negotiate away access to life-saving drugs in the name of free trade,' said Gargeya Telakapalli, a public health campaigner based in Hyderabad. 'The poorest Indians—those with cancer, HIV, diabetes, or TB—are being quietly sacrificed.' Broader implications The deal follows a similar agreement India signed last year with the European Free Trade Association (EFTA), which also faced criticism for diluting IP safeguards. Observers say the trend may reflect a shift in India's trade policy as it seeks closer ties with Western economies. But for many in India's healthcare and legal communities, the question remains: how much access to medicine is the country willing to give up for a better trade balance? From Westminster to Washington DC - our political experts are across all the latest key talking points. Listen to the latest episode below...
Metro
40 minutes ago
- Metro
Health warning over counterfeit vodka made with medical-grade alcohol
Health officials in Scotland have warned fans of Glen's vodka to keep an eye out for fake half bottles containing medical disinfectant. Scammers have hijacked the popular brand to sell counterfeit products containing the chemical isopropyl, which is typically used in hospital settings or in hand sanitiser. Food Standards Scotland (FSS) say the fake booze will smell and taste 'very different' to the Glen's product people recognise. Even small amounts of isopropyl can result in abdominal pain, vomiting, dizziness and headaches, they warned. Severe cases can leave drinkers in a coma or even dead. Genuine bottles of Glen's have a laser-etched code between the rear label and the base of the bottle which the fake bottles will not. More Trending Anyone concerned they might have drunk the counterfeit vodka, and who is experiencing symptoms, is urged to contact NHS 24 on 111 immediately. Glen's, one of the cheaper brands of vodka on the market, is a popular target for scammers. FSS has previously sent investigators to seize dozens of bottles of fake spirit using the same label from a shop in Coatbridge, Lanarkshire. And in September last year, the UK-wide Food Standards Agency sent out a warning about another fraud involving isopropyl alcohol in Glen's bottles. Get in touch with our news team by emailing us at webnews@ For more stories like this, check our news page. MORE: The one drink you should never order from a restaurant wine list MORE: How a generation-bending TikTok campaign saved a local boozer MORE: Forget about Prosecco — drink this £6.97 sparkling wine from Asda instead
The Independent
40 minutes ago
- The Independent
NHS: Strike-hit appointments to be rebooked in two weeks but will impact others
NHS England has said hospitals are aiming to reschedule appointments cancelled due to strikes within two weeks, but warned of knock-on impacts for other patients. Professor Meghana Pandit, NHS England's co-national medical director (secondary care), said that despite the five-day walkout by thousands of resident doctors in England, which began on Friday, local trusts have managed to maintain services with 'minimal disruption'. She told BBC Breakfast: 'If there's any rescheduling or postponement of surgery or appointments then the hospitals try their upmost best to get that appointment rescheduled within two weeks. 'I know it is distressing and even two weeks is too long for somebody to wait and actually that has an impact on the people who who are then displaced at that two week period.' Prof Pandit said there were three 'derogations' granted on Friday, a process which allows hospitals to request striking doctors return to work if there is a risk to patient safety. Nottingham City Hospital reached an agreement with the British Medical Association (BMA) to exempt one doctor from the strike to work on the neonatal intensive care unit. A derogation was agreed for one doctor in the emergency department and another doctor in the ISGM at the Northern General Hospital. The BMA said it had also agreed a derogation for two anaesthetists to work at University Hospital Lewisham on Saturday to ensure patient safety. It comes as Wes Streeting said 'we are doing everything we can to minimise' patient harm. The Health Secretary condemned the strike as 'reckless' and said the Government would not allow the BMA to 'hold the country to ransom'. Sir Keir Starmer made a last-minute appeal to resident doctors, saying the strikes would 'cause real damage'. He added: 'Most people do not support these strikes. They know they will cause real damage… 'These strikes threaten to turn back the clock on progress we have made in rebuilding the NHS over the last year, choking off the recovery.' The BMA has argued that real-terms pay has fallen by around 20% since 2008, and is pushing for full 'pay restoration'.
